Physician profile
Jane Fang
NPI 1487702882
$2,627.65
in general payments reported to CMS, 2019-2025
33 companies · $485 in 2025
The $485 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $231 · 2021: $555 · 2022: $322 · 2023: $306 · 2024: $236 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987 · Education: $40.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.33 |
| Education | $40.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $300.60 | 2019-2023 | |
| Amgen INC. | $190.49 | 2019-2023 | Prolia, Evenity |
| Coopersurgical, INC. | $178.28 | 2020-2025 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $173.15 | 2019-2025 | |
| Therapeuticsmd, INC. | $167.30 | 2019-2021 | |
| Ethicon US, LLC | $158.78 | 2021-2025 | Dermabond, Stratafix, Harmonic |
| Hologic Sales and Service, LLC | $130.28 | 2020-2025 | Myosure Tissue Removal Device, Aptima, Acessa Provu System |
| Amag Pharmaceuticals, INC. | $110.87 | 2019 | |
| Millicent US INC | $102.79 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Astellas Pharma US INC | $87.09 | 2023-2025 | Veozah |
| Evofem Biosciences, INC. | $86.70 | 2021 | |
| Merck Sharp & Dohme LLC | $81.53 | 2019-2020 | |
| Biogen, INC. | $80.90 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $79.74 | 2021-2023 | |
| Organon LLC | $79.53 | 2021-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $62.41 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $57.94 | 2021-2025 | |
| Shield Therapeutics INC | $53.74 | 2023-2025 | Accrufer |
| Ge Healthcare | $49.67 | 2023 | |
| Minerva Surgical, INC | $47.61 | 2025 | |
| Exact Sciences Corporation | $44.67 | 2023 | Cologuard Collection Kit |
| Medicem INC. | $42.49 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $39.49 | 2019 | |
| Mallinckrodt Enterprises LLC | $31.15 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $26.72 | 2025 | |
| Stryker Corporation | $24.80 | 2023 | Universal Neuro 3 |
| Sage Therapeutics, LLC | $24.80 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $24.49 | 2021 | |
| Medtronic, INC. | $21.14 | 2023 | Truclear |
| Avanos Medical | $21.03 | 2021 | |
| Octapharma USA, INC. | $19.99 | 2025 | Fibryga |
| Avion Pharmaceuticals | $15.33 | 2022 | |
| Channel Medsystems, INC. | $12.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Fang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.